Permanente interstitielle Brachytherapie (Seed-Implantation) bei ...

11. Anhang
11.13. Nomogramme zur Prognoseabschätzung und Therapieauswahl
Update der Partin-Tabellen von 2001 bzgl. der Tumorstadien T1c, T2a, T2b und T2c
Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD (2001) Contemporary update of prostatic cancer staging nomograms
(Partin tables) for the new millenium. Urology 58: 843-848
PSA Range
(ng/mL)
0-2.5
TABLE I. Clinical Stage T1c (nonpalpable, PSA elevated)
Pathologic Stage
2-4 5-6
Gleason Score
3+4=7 4+3=7 8-10
Organ confined 95 (89-99) 90 (88-93) 79 (74-85) 71 (62-79) 66 (54-76)
Extraprostatic extension 5 (1-11) 9 (7-12) 17 (13-23) 25 (18-34) 28 (20-38)
Seminal vesicle (+) — 0 (0-1) 2 (1-5) 2 (1-5) 4 (1-10)
Lymph node (+) — 1 (0-2) 1 (0-4) 1 (0-4)
Organ confined 92 (82-98) 84 (81-86) 68 (62-74) 58 (48-67) 52 (41-63)
2.6-4.0
Extraprostatic extension
Seminal vesicle (+)
8 (2-18)
—
15 (13-18)
1 (0-1)
27 (22-33)
4 (2-7)
37 (29-46)
4 (1-7)
40 (31-50)
6 (3-12)
Lymph node (+) — — 1 (0-2) 1 (0-3) 1 (0-4)
Organ confined 90 (78-98) 80 (78-83) 63 (58-68) 52 (43-60) 46 (36-56)
4.1-6.0
Extraprostatic extension
Seminal vesicle (+)
10 (2-22)
—
19 (16-21)
1 (0-1)
32 (27-36)
3 (2-5)
42 (35-50)
3 (1-6)
45 (36-54)
5 (3-9)
Lymph node (+) — 0 (0-1) 2 (1-3) 3 (1-5) 3 (1-6)
Organ confined 87 (73-97) 75 (72-77) 54 (49-59) 43 (35-51) 37 (28-46)
6.1-10.0
Extraprostatic extension
Seminal vesicle (+)
13 (3-27)
—
23 (21-25)
2 (2-3)
36 (32-40)
8 (6-11)
47 (40-54)
8 (4-12)
48 (39-57)
13 (8-19)
Lymph node (+) — 0 (0-1) 2 (1-3) 2 (1-4) 3 (1-5)
Organ confined 80 (61-95) 62 (58-64) 37 (32-42) 27 (21-34) 22 (16-30)
>10.0
Extraprostatic extension
Seminal vesicle (+)
20 (5-39)
—
33 (30-36)
4 (3-5)
43 (38-48)
12 (9-17)
51 (44-59)
11 (6-17)
50 (42-59)
17 (10-25)
Lymph node (+) — 2 (1-3) 8 (5-11) 10 (5-17) 11 (5-18)
KEY: PSA = prostate-specific antigen.
PSA Range
(ng/mL)
0-2.5
2.6-4.0
4.1-6.0
6.1-10.0
>10.0
TABLE II. Clinical Stage T2a (palpable < 1 .2 of one lobe))
Pathologic Stage
Gleason Score
2-4 5-6 3+4=7 4+3=7 8-10
Organ confined 91 (79-98) 81 (77-85) 64 (56-71) 53 (43-63) 47 (35-59)
Extraprostatic extension 9 (2-21) 17 (13-21) 29 (23-36) 40 (30-49 42 (32-53)
Seminal vesicle (+) — 7 (2-16) 1 (0-2) 5 (1-9) 4 (1-9) 7 (2-16)
Lymph node (+) — 0 (0-1) 2 (0-5) 3 (0-8) 3 (0-9)
Organ confined 85 (69-96)) 71 (66-75) 50 (43-57) 39 (30-48) 33 (24-44
Extraprostatic extension 15 (4-31) 27 (23-31) 41 (35-48) 52 (43-61) 53 (44-63)
Seminal vesicle (+) — 2 (1-3) 7 (3-12) 6 (2-12) 10 (4-18)
Lymph node (+) — 0 (0-1) 2 (0-4) 2 (0-6) 3 (0-8)
Organ confined 81 (63-95) 66 (62-70) 44 (39-50) 33 (25-41) 28 (20-37)
Extraprostatic extension 19 (5-37) 32 (28-36) 46 (40-52) 56 (48-64) 58 (49-66)
Seminal vesicle (+) — 1 (1-2) 5 (3-8) 5 (2-8) 8 (4-13)
Lymph node (+) — 1 (0-2) 4 (2-7) 6 (3-11) 6 (2-12)
Organ confined 76 (56-94) 58 (54-61) 35 (30-40) 25 (19-32) 21 (15-28)
Extraprostatic extension 24 (6-44) 37 (34-41) 49 (43-54) 58 (51-66) 57 (48-65)
Seminal vesicle (+) — 4 (3-5) 13 (9-18) 11 (6-17) 17 (11-26)
Lymph node (+) — 1 (0-2) 3 (2-6) 5 (2-8) 5 (2-10)
Organ confined 65 (43-89) 42 (38-46) 20 (17-24) 14 (10-18) 11 (7-15)
Extraprostatic extension 35 (11-57) 47 (43-52) 49 (43-55) 55 (46-64) 52 (41-62)
Seminal vesicle (+) — 6 (4-8) 16 (11-22) 13 (7-20) 19 (12-29)
Lymph node (+) — 4 (3-7) 14 (9-21) 18 (10-27) 17 (9-29)
398/415
HTA zur permanenten interstitiellen Brachytherapie, copyright KBV und Bundesärztekammer